Rachel Stadelmaier1,2, Hanah Nasri2,3, Curtis K Deutsch4, Margaret Bauman5, Anne Hunt6, Christopher J Stodgell7, Jane Adams8, Lewis B Holmes2,3. 1. Albert Einstein College of Medicine, Bronx, New York. 2. The Medical Genetics Unit, MassGeneral Hospital for Children, Boston, Massachusetts. 3. Department of Pediatrics, Harvard Medical School, Boston, Massachusetts. 4. The Psychobiology Program at the Eunice Kennedy Shriver Center and Departments of Psychiatry and Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts. 5. Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, Massachusetts. 6. Hunt Consulting Associates, Chapel Hill, North Carolina. 7. Department of OB/GYN, University of Rochester School of Medicine & Dentistry, Rochester, New York. 8. Department of Psychology, UMass-Boston, Boston, Massachusetts.
Abstract
BACKGROUND: Valproic acid (VPA) is the most teratogenic anticonvulsant drug in clinical use today. Children exposed prenatally to VPA have previously been shown to have dysmorphic craniofacial features, identified subjectively but not by anthropometric methods. Exposure to VPA has also been associated with an increased frequency of autism spectrum disorder (ASD). An increased cephalic index (the ratio of the cranial lateral width to the cranial anterior-posterior length) has been observed in children with ASD. METHODS: Forty-seven children exposed to VPA during the first trimester of pregnancy were evaluated for dysmorphic facial features, identified subjectively and by measurements. Each VPA-exposed child was evaluated for ASD using the Social Communication Questionnaire, Autism Diagnostic Interview-Revised, and Autism Diagnostic Observation Schedule. The same physical examination was carried out on an unexposed comparison group of 126 children. The unexposed children also had testing for cognitive performance by the Wechsler Intelligence Scale for Children. RESULTS: Several dysmorphic craniofacial features, including telecanthus, wide philtrum, and increased length of the upper lip were identified subjectively. Anthropometric measurements confirmed the increased intercanthal distance and documented additional findings, including an increased cephalic index and decreased head circumference/height index. There were no differences between the craniofacial features of VPA-exposed children with and without ASD. CONCLUSION: An increased frequency of dysmorphic craniofacial features was identified in children exposed to VPA during the first trimester of pregnancy. The most consistent finding was a larger cephalic index, which indicates a disproportion of increased width of the skull relative to the shortened anterior-posterior length. Birth Defects Research 109:1134-1143, 2017.
BACKGROUND:Valproic acid (VPA) is the most teratogenic anticonvulsant drug in clinical use today. Children exposed prenatally to VPA have previously been shown to have dysmorphic craniofacial features, identified subjectively but not by anthropometric methods. Exposure to VPA has also been associated with an increased frequency of autism spectrum disorder (ASD). An increased cephalic index (the ratio of the cranial lateral width to the cranial anterior-posterior length) has been observed in children with ASD. METHODS: Forty-seven children exposed to VPA during the first trimester of pregnancy were evaluated for dysmorphic facial features, identified subjectively and by measurements. Each VPA-exposed child was evaluated for ASD using the Social Communication Questionnaire, Autism Diagnostic Interview-Revised, and Autism Diagnostic Observation Schedule. The same physical examination was carried out on an unexposed comparison group of 126 children. The unexposed children also had testing for cognitive performance by the Wechsler Intelligence Scale for Children. RESULTS: Several dysmorphic craniofacial features, including telecanthus, wide philtrum, and increased length of the upper lip were identified subjectively. Anthropometric measurements confirmed the increased intercanthal distance and documented additional findings, including an increased cephalic index and decreased head circumference/height index. There were no differences between the craniofacial features of VPA-exposed children with and without ASD. CONCLUSION: An increased frequency of dysmorphic craniofacial features was identified in children exposed to VPA during the first trimester of pregnancy. The most consistent finding was a larger cephalic index, which indicates a disproportion of increased width of the skull relative to the shortened anterior-posterior length. Birth Defects Research 109:1134-1143, 2017.
Authors: E Jäger-Roman; A Deichl; S Jakob; A M Hartmann; S Koch; D Rating; R Steldinger; H Nau; H Helge Journal: J Pediatr Date: 1986-06 Impact factor: 4.406
Authors: Janet E Lainhart; Erin D Bigler; Maureen Bocian; Hilary Coon; Elena Dinh; Geraldine Dawson; Curtis K Deutsch; Michelle Dunn; Annette Estes; Helen Tager-Flusberg; Susan Folstein; Susan Hepburn; Susan Hyman; William McMahon; Nancy Minshew; Jeff Munson; Kathy Osann; Sally Ozonoff; Patricia Rodier; Sally Rogers; Marian Sigman; M Anne Spence; Christopher J Stodgell; Fred Volkmar Journal: Am J Med Genet A Date: 2006-11-01 Impact factor: 2.802
Authors: Janneke Jentink; Maria A Loane; Helen Dolk; Ingeborg Barisic; Ester Garne; Joan K Morris; Lolkje T W de Jong-van den Berg Journal: N Engl J Med Date: 2010-06-10 Impact factor: 91.245
Authors: Stephan J Sanders; Michael T Murtha; Abha R Gupta; John D Murdoch; Melanie J Raubeson; A Jeremy Willsey; A Gulhan Ercan-Sencicek; Nicholas M DiLullo; Neelroop N Parikshak; Jason L Stein; Michael F Walker; Gordon T Ober; Nicole A Teran; Youeun Song; Paul El-Fishawy; Ryan C Murtha; Murim Choi; John D Overton; Robert D Bjornson; Nicholas J Carriero; Kyle A Meyer; Kaya Bilguvar; Shrikant M Mane; Nenad Sestan; Richard P Lifton; Murat Günel; Kathryn Roeder; Daniel H Geschwind; Bernie Devlin; Matthew W State Journal: Nature Date: 2012-04-04 Impact factor: 49.962
Authors: Kimford J Meador; Gus A Baker; Nancy Browning; Morris J Cohen; Rebecca L Bromley; Jill Clayton-Smith; Laura A Kalayjian; Andres Kanner; Joyce D Liporace; Page B Pennell; Michael Privitera; David W Loring Journal: Lancet Neurol Date: 2013-01-23 Impact factor: 44.182
Authors: Holly A F Stessman; Marjolein H Willemsen; Michaela Fenckova; Osnat Penn; Alexander Hoischen; Bo Xiong; Tianyun Wang; Kendra Hoekzema; Laura Vives; Ida Vogel; Han G Brunner; Ineke van der Burgt; Charlotte W Ockeloen; Janneke H Schuurs-Hoeijmakers; Jolien S Klein Wassink-Ruiter; Connie Stumpel; Servi J C Stevens; Hans S Vles; Carlo M Marcelis; Hans van Bokhoven; Vincent Cantagrel; Laurence Colleaux; Michael Nicouleau; Stanislas Lyonnet; Raphael A Bernier; Jennifer Gerdts; Bradley P Coe; Corrado Romano; Antonino Alberti; Lucia Grillo; Carmela Scuderi; Magnus Nordenskjöld; Malin Kvarnung; Hui Guo; Kun Xia; Amélie Piton; Bénédicte Gerard; David Genevieve; Bruno Delobel; Daphne Lehalle; Laurence Perrin; Fabienne Prieur; Julien Thevenon; Jozef Gecz; Marie Shaw; Rolph Pfundt; Boris Keren; Aurelia Jacquette; Annette Schenck; Evan E Eichler; Tjitske Kleefstra Journal: Am J Hum Genet Date: 2016-03-03 Impact factor: 11.043
Authors: Ushma Mehta; Mariette Smith; Emma Kalk; Helen Hayes; Annoesjka Swart; Lawrence Tucker; Renier Coetzee; Andrew Boulle; Marc Blockman Journal: Drug Saf Date: 2021-01 Impact factor: 5.606